GT Biopharma, Inc.
GTBP
$0.42
-$0.01-2.26%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.48% | -23.17% | -23.64% | -4.37% | 20.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.52% | -23.09% | -18.63% | 1.56% | 5.80% |
| Operating Income | 13.52% | 23.09% | 18.63% | -1.56% | -5.80% |
| Income Before Tax | -115.42% | 26.33% | 17.25% | -21.13% | -73.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -115.42% | 26.33% | 17.25% | -21.13% | -73.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -115.42% | 26.33% | 17.25% | -21.13% | -73.25% |
| EBIT | 13.52% | 23.09% | 18.63% | -1.56% | -5.80% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 43.89% | 54.84% | 47.18% | 19.08% | -24.93% |
| Normalized Basic EPS | 45.22% | 50.08% | 42.11% | 13.31% | -13.89% |
| EPS Diluted | 43.89% | 54.84% | 47.18% | 19.08% | -24.93% |
| Normalized Diluted EPS | 45.22% | 50.08% | 42.11% | 13.31% | -13.89% |
| Average Basic Shares Outstanding | 190.53% | 68.68% | 64.50% | 56.34% | 46.69% |
| Average Diluted Shares Outstanding | 190.53% | 68.68% | 64.50% | 56.34% | 46.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |